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Background: Severe anaemia in children is a leading cause of hospital admission and a major cause of mortality in
sub-Saharan Africa, yet there are limited published data on blood transfusion in this vulnerable group.
Methods: We present data from a large controlled trial of fluid resuscitation (Fluid Expansion As Supportive
Therapy (FEAST) trial) on the prevalence, clinical features, and transfusion management of anaemia in children
presenting to hospitals in three East African countries with serious febrile illness (predominantly malaria and/or
sepsis) and impaired peripheral perfusion.
Results: Of 3,170 children in the FEAST trial, 3,082 (97%) had baseline haemoglobin (Hb) measurement, 2,346/3,082
(76%) were anaemic (Hb <10 g/dL), and 33% severely anaemic (Hb <5 g/dL). Prevalence of severe anaemia varied
from 12% in Kenya to 41% in eastern Uganda. 1,387/3,082 (45%) children were transfused (81% within 8 hours).
Adherence to WHO transfusion guidelines was poor. Among severely anaemic children who were not transfused,
52% (54/103) died within 8 hours, and 90% of these deaths occurred within 2.5 hours of randomisation. By
24 hours, 128/1,002 (13%) severely anaemic children had died, compared to 36/501 (7%) and 71/843 (8%) of those
with moderate and mild anaemia, respectively. Among children without severe hypotension who were randomised
to receive fluid boluses of 0.9% saline or albumin, mortality was increased (10.6% and 10.5%, respectively) compared
to controls (7.2%), regardless of admission Hb level. Repeat transfusion varied from ≤2% in Kenya/Tanzania to 6 to
13% at the four Ugandan centres. Adverse reactions to blood were rare (0.4%).
Conclusions: Severe anaemia complicates one third of childhood admissions with serious febrile illness to hospitals
in East Africa, and is associated with increased mortality. A high proportion of deaths occurred within 2.5 hours of
admission, emphasizing the need for rapid recognition and prompt blood transfusion. Adherence to current WHO
transfusion guidelines was poor. The high rates of re-transfusion suggest that 20 mL/kg whole blood or 10 mL/kg
packed cells may undertreat a significant proportion of anaemic children. Future evaluation of the impact of a larger
volume of transfused blood and optimum transfusion management of children with Hb of <6 g/dL is warranted.
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In sub-Saharan Africa, severe anaemia in children is a
leading cause of hospital admission, a major cause of
mortality [1,2], and is responsible for a high proportion
of the 660,000 malaria-related deaths that are estimated
to occur each year [3,4]. Although timely transfusion can
be lifesaving, equitable access to adequate supplies of safe
blood for transfusion remains a key challenge in sub-
Saharan Africa. In order to preserve this scarce resource
and to reduce the risk of transfusion-transmitted in-
fections, guidelines developed by the World Health
Organization (WHO) encourage the rational use of blood
transfusion [5]. However, adherence to the guidelines is
variable, and transfusion recommendations vary between
countries [6-8]. There are limited published data on blood
transfusion of anaemic children in sub-Saharan Africa,
particularly in relation to re-transfusion [9-11]. A large
randomised controlled trial of fluid resuscitation (the Fluid
Expansion As Supportive Therapy (FEAST) trial [12]) pro-
vided an opportunity to present quality-controlled data on
the prevalence, clinical features, and transfusion manage-
ment of anaemia in children presenting to hospitals in
three East African countries with serious febrile illness
and clinical signs of impaired peripheral perfusion.
Methods
The FEAST trial was conducted between January 2009
and January 2011 at six centres in three East African
countries (Kenya: Kilifi District Hospital; Tanzania: Teule
District Hospital, Muheza; Uganda: Mulago National Re-
ferral Hospital, Kampala; St Marys Hospital, Lacor; Soroti
and Mbale Regional Referral Hospitals, Eastern Uganda).
Malaria transmission at all sites in Uganda was perennial
and intense, particularly in Eastern Uganda, while trans-
mission in Kilifi and Muheza was predominantly seasonal
and of low to moderate intensity during the period of
the trial [13]. The study was registered on the 29th of
November, 2008 (ISRCTN69856593).
Study population
Eligible children were between 60 days and 12 years of
age, and presented with severe febrile illness complicated
by impaired consciousness (prostration or coma) and/or
respiratory distress (increased work of breathing), plus at
least one sign of impaired peripheral perfusion (capillary
refill time of 3 seconds or more, lower limb temperature
gradient, weak radial pulse volume, or severe tachycardia
(see footnotes to Table 1 for all clinical definitions).
FEAST trial randomisation strategy
Children were randomised to receive immediate boluses
of 20 to 40 mL/kg of 5% human albumin solution or
0.9% saline solution over one hour, or maintenance
fluids at 4 mL/kg/hour until able to drink (no boluscontrol group). Those with severe hypotension were
randomly assigned to receive 40 mL/kg bolus of either
albumin or saline. Children with severe malnutrition,
gastroenteritis, trauma, surgery, burns, and conditions
for which volume expansion would be contraindicated
were excluded from the trial. The primary endpoint was
mortality at 48 hours after randomisation. Consent and
ethical approval are detailed elsewhere [12]. Saline and
albumin were provided by Baxter BioScience, Vienna.
Clinical management
Venous blood was taken on admission for immediate
measurement of haemoglobin (Hb), blood glucose, lac-
tate, malaria parasitaemia, and HIV status. Hb was mea-
sured using the HaemoCue Hb 301 system (HaemoCue
AB, Angelholm, Sweden), a portable point of care Hb
testing kit that is factory calibrated (without need for re-
calibration), and using disposable microcuvettes that re-
quire no calibration between batches. The measurement
range is 0 to 25.6 g/dL, and results are available in
10 seconds. Children were managed on general paediat-
ric wards, with no facilities for ventilation other than
short-term ‘bag and mask’ support. Training in triage,
identification, and definitions of adverse events related
to fluid management (including transfusion) were given
prior to and throughout the trial, and were included in
the trial manual of operations that was given to every
team member.
Blood transfusion
Clinicians at all sites followed national and WHO blood
transfusion guidelines (Table 2). Children with Hb ≤4 g/dL,
regardless of clinical symptoms, were transfused with
20 mL/kg whole blood or 10 mL/kg packed cells, given
over 4 hours, and started as soon as possible after the
first bolus of resuscitation fluid, if randomised to bolus.
Children with Hb 5 to 6 g/dL were transfused if they
had one or more clinical or laboratory features of seve-
rity (Table 2). Use of frusemide or other diuretics was
confined to children with clinical signs of pulmonary
oedema. Hb levels were checked at 8, 24, and 48 hours
post-randomisation, and at any other time point if there
was clinical suspicion of severe anaemia or deterior-
ation. Repeat blood transfusion was permitted when Hb
levels fell below transfusion thresholds. Any severe ad-
verse events were reviewed by the attending clinician
and subsequently reviewed by the trial oversight and
ethical review committees.
Statistical analysis
Children were classified as having severe anaemia
(Hb <5 g/dL), moderate anaemia (Hb 5 to <7 g/dL),
mild anaemia (Hb 7 to <10 g/dL), or no anaemia
(Hb ≥10 g/dL) on the basis of admission Hb levels
Table 1 Clinical characteristics at baseline by level of haemoglobin
Severe anaemia
(Hb <5 g/dL)
Moderate anaemia
(5 to <7 g/dL)
Mild anaemia
(7 to <10 g/dL)
No anaemia
(≥10 g/dL)
Total P value
N (%)1 1,002 (33%) 501 (16%) 843 (27%) 736 (24%) 3,082
General
Age (months); median (IQR) 25 (15, 42) 23 (13, 36) 19 (12, 34) 24 (14, 45) 24 (13, 38) 0.02
Female 439 (44%) 245 (49%) 367 (44%) 364 (49%) 1415 (46%) 0.1
Weight-for-age z-score; median (IQR) −1.6 −1.6 −1.5 −1.3 −1.5 <0.001
(−2.5, –0.8) (−2.6, –0.8) (−2.4, –0.6) (−2.2, −0.5) (−2.4, −0.7)
Axillary Temperature >39°C 109 (11%) 119 (24%) 261 (31%) 234 (32%) 723 (24%) <0.001
Respiratory
Respiratory rate; mean (SD) 56.1 (13.8) 56.5 (14.5) 60.3 (15.8) 58.0 (16.6) 57.8 (15.3) <0.001
Respiratory distress 845 (85%) 410 (82%) 694 (83%) 574 (78%) 2,523 (82%) 0.001
Chest indrawing 686 (69%) 322 (64%) 576 (68%) 483 (66%) 2,067 (67%) 0.39
Deep breathing 745 (75%) 329 (66%) 485 (58%) 424 (58%) 1,983 (65%) <0.001
Oxygen saturation ≤90% 260 (28%) 107 (22%) 187 (23%) 195 (27%) 749 (25%) 0.36
Cardiovascular
Weak radial pulse 298 (29%) 113 (23%) 139 (16%) 107 (15%) 657 (21%) <0.001
Lower limb temperature gradient2 661 (66%) 295 (59%) 467 (55%) 394 (53%) 1,883 (59%) <0.001
Capillary refill time (3 or more seconds) 573 (57%) 115 (23%) 80 (9%) 50 (7%) 818 (27%) <0.001
Severe tachycardia3 616 (62%) 377 (75%) 623 (74%) 544 (74%) 2,160 (70%) <0.001
Bradycardia 18 (2%) 3 (<1%) 6 (<1%) 8 (1%) 35 (1%) 0.11
Systolic blood pressure; median (IQR) 88 (81, 96) 93 (86, 101) 94 (86, 102) 98 (89, 106) 93 (85, 101) <0.001
Moderate hypotension4 100 (10%) 25 (5%) 43 (5%) 19 (3%) 187 (6%) <0.001
Hypothermia (temperature <36°C) 98 (10%) 24 (5%) 27 (3%) 41 (6%) 190 (6%) <0.001
Dehydration (sunken eyes or reduced
skin turgor)
105 (11%) 46 (9%) 51 (6%) 34 (5%) 236 (8%) <0.001
Anaemia
Severe pallor (pale mucous membranes) 989 (99%) 381 (77%) 167 (20%) 38 (5%) 1,575 (51%) <0.001
Haemoglobinuria (history of dark urine) 282 (28%) 62 (12%) 32 (4%) 9 (1%) 385 (13%) <0.001
Clinical jaundice 584 (58%) 200 (40%) 155 (18%) 35 (5%) 974 (32%) <0.001
Neurological
Prostrate5 726 (73%) 328 (66%) 466 (55%) 387 (53%) 1,907 (62%) <0.001
Coma6 129 (13%) 89 (18%) 142 (17%) 98 (13%) 458 (15%) 0.55
Convulsions in this illness 264 (27%) 212 (42%) 358 (42%) 320 (44%) 1,154 (37%) <0.001
Laboratory tests
Positive malaria parasitaemia7 593 (59%) 377 (75%) 462 (55%) 317 (43%) 1,749 (57%) <0.001
Hyperparasitaemia8 34/592 (6%) 41/308 (13%) 42/569 (7%) 32/504 (6%) 149/1,973 (8%) 0.86
Glucose <2.5 mmol/L 52 (5%) 28 (6%) 31 (4%) 23 (3%) 134 (5%) 0.02
Lactate ≥5 mmol/L 672 (70%) 218 (45%) 184 (23%) 75 (11%) 1,149 (39%) <0.001
Base deficit >8 392/632 (62%) 189/329 (58%) 254/554 (45%) 239/539 (44%) 1,074/2,054 (52%) <0.001
Severe acidaemia (pH <7.2) 97/635 (15%) 38/291 (12%) 48/556 (9%) 30/511 (6%) 213/2,061 (10%) 0.82
Hyperkalaemia (>6.5 mmol/L) 83/630 (13%) 41/330 (12%) 54/559 (10%) 28/536 (5%) 206/2,055 (10%) <0.001
HIV antibody positive 17/790 (2%) 25/390 (6%) 36/666 (5%) 31/615 (5%) 109/2,461 (4%) 0.008
Positive blood culture 25/234 (11%) 32/179 (18%) 36/341 (11%) 35/317 (10%) 128/1,071 (12%) 0.52
1Of 3,170 children enrolled in the FEAST trial, 88 did not have haemoglobin measured at baseline.
2Temperature gradient was assessed by running the back of the hand from the toe to the knee; a positive temperature gradient was defied as a notable
temperature change from cold (dorsum of foot) to warm (knee).
3Severe tachycardia was defined as >180 beats per minute (bpm) in children <12 months, >160 bpm in children aged 12 months to 5 years, and >140 bpm for
those aged >5 years.
4Moderate hypotension was defined as systolic blood pressure of 50 to 75 mmHg in children younger than 12 months, 60 to 75 mmHg in those 12 months to
5 years, and 70 to 85 mmHg in those older than 5 years, as measured by automated blood pressure monitor.
5Prostration was defined as the inability of a child older than 8 months of age to sit upright or the inability of a child 8 months of age or younger to breast feed.
6Coma was defined as the inability to localise a painful stimulus.
7Positive on quality-controlled malaria slide, or, if missing, on rapid diagnostic test.
8Parasite count >250,000 per μL or, for 133 children in whom quantitative parasite count was unavailable, percentage parasitaemia >10%. No information on
parasite density was available for 1,109/3,082 (36%) children.
IQR, Interquartile range; SD, Standard deviation.
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all groups using the χ2 test for trend across categorised
variables, non-parametric test of medians across ordered
groups, and linear regression for comparison of means.
The prevalence of anaemia, jaundice, and malaria, number
of blood transfusions, and mortality at 48 hours and
28 days were summarised by site. Kaplan-Meier graphs
were plotted, showing time from randomisation to the
start of blood transfusion by baseline Hb level (Figure 1)
and by site (Additional file 1: Figure S1), with children
censored at the time transfusion started, time of death, or
48 hours after randomisation (whichever occurred first).
Inter-site differences were examined with the log-rank
test. Forest plots were constructed to compare 48-hour
mortality in the fluid bolus and control groups according
to Hb level (Figure 2) and anaemia category (severe, mod-
erate, mild, or no anaemia; Figure 3) at the time of
admission.Table 2 Blood transfusion guidelines used by clinicians in the
Guidelines Indications for transfusion
Haemoglobin
level (g/dL)
WHO Pocket Book of Hospital Care
for Children (2005)*
4 or less
OR
6 or less PLUS 1 or more
Kenya Guidelines for Appropriate Use of
Blood and Blood Products (2004)*
Less than 4
OR
Less than 5 PLUS
Ugandan National Guidelines (2010)* 4 or less
OR
6 or less PLUS 1 or more
Tanzania National Malaria
Guidelines (2006)*
4 or less
OR
6 or less PLUS
*Version of guidelines available at the time of the FEAST trial.Although WHO guidelines recommend transfusion for
all children with Hb ≤4 g/dL, guidance is less clear in re-
lation to children with Hb of 5 to 6 g/dL, for whom
transfusion is only recommended in the presence of one
or more pre-specified clinical and laboratory features
[5]. To assess adherence to WHO guidelines within the
FEAST trial, we therefore examined the factors most
strongly associated with blood transfusion in children
with Hb ≥5 g/dL. A time-updated Cox regression model
for time to first transfusion was fitted for those with
baseline Hb of ≥5 g/dL. Regression models were first
calculated for each risk factor individually, adjusting for
randomisation arm, Hb at baseline, and most recent Hb
at 8 or 24 hours. A multivariable, time-updated Cox re-
gression model, similarly adjusted, was then constructed
by stepwise backwards elimination, including study site
and clinical indications for transfusion, where available
(Table 3). Using variables found to be risk factors forFEAST trial
Volume and speed of transfusion
Clinical symptoms
Not required 20 mL/kg whole blood or 10 mL/kg
packed cells over 3 to 4 hours
Deep and laboured breathing
Cardiac failure
Clinical dehydration
Shock
Impaired consciousness
Malaria parasitaemia >10%
Not required 20 mL/kg whole blood over 3 to
4 hours
Respiratory distress
Not required 20 mL/kg whole blood or 10 mL/kg
packed cells over 3 to 4 hours
Hypoxia
Cardiac decompensation
Acidosis
Impaired consciousness
Cerebral malaria
Septicaemia
Meningitis
Malaria parasitaemia >20%
Not required 20 mL/kg whole blood or 10 mL/kg
packed cells over 3 to 4 hours
Cardiac failure
Figure 1 Kaplan Meier curves of time to first transfusion, by anaemia category.
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adjusted for randomisation arm, was used to describe
baseline risk factors for re-transfusion. Sub-group analyses
by Hb level and blood transfusion were pre-specified,
while other analyses were performed post hoc.Study oversight
The ethics committees at Imperial College, London,
Makerere University, Uganda, Medical Research Institute,
Kenya, and National Medical Research Institute, Tanzania,
approved the protocol. In cases in which prior written
consent from parents of guardians could not be obtained,
provision was made for oral assent from a legal surrogate,
followed by delayed written informed consent as soon as
practicable. Initial boluses were increased to from 20 to
40 mL/kg (and 40 to 60 mL/kg in those with severe
hypotension) in a protocol amendment dated August 2010
and approved by all ethics committees.Results
Prevalence and clinical presentation of anaemia
Of 3,170 children in the FEAST trial, 3,082 (97%) had a
baseline Hb measurement, and 2,346/3,082 (76%) were
anaemic (Table 1); 1,002/3,082 (33%) children had severe
anaemia, 501 (16%) moderate anaemia, and 843 (27%)
mild anaemia. Children with moderate or severe anae-
mia had worse nutritional status than those with mild
anaemia or no anaemia. A greater proportion of severely
anaemic children had impaired peripheral perfusion, mo-
derate hypotension, low core temperature, dehydration,
respiratory distress, and prostration compared to those
with mild or moderate anaemia and non-anaemic children
(P ≤0.001 for all comparisons). The proportion of childrenwith oxygen saturation ≤90% did not differ significantly
between groups. Severe pallor, jaundice, dark urine, meta-
bolic acidosis, and hyperkalaemia were more common in
children with severe anaemia (P ≤0.001 for all compari-
sons). Malaria parasitaemia was present in 1,749/3,082
(57%) children, with a higher proportion of anaemic
children being parasitaemic compared to non-anaemic
children (59%, 75%, and 55% for severe, moderate, and
mild anaemia, respectively, versus 43% for no anaemia;
P <0.001). Among those children in whom malaria
parasitaemia was quantified, 149/1,973 (8%) had hyper-
parasitaemia, with no significant differences between
anaemic and non-anaemic children. Overall, 128/1,071
(12%) blood cultures were positive, with no significant
difference between groups; 109/2,461 (4%) children
tested HIV antibody positive.
The prevalence of severe anaemia was lowest in Kilifi,
Kenya (13%), and highest in Mbale (39%) and Soroti
(43%), Eastern Uganda (Table 4). Haemoglobinuria was
uncommon (≤2%) in Kenya and Tanzania, but occurred
in ~20% of children presenting to Mbale and Soroti,
often in association with jaundice (Table 4).Blood transfusion
Number and type of transfusion
Overall, 1,387/3,082 (45%) children were transfused, of
whom 23% (317/1,387) required re-transfusion; 81%
(1,118/1,387) were transfused within 8 hours of admission.
The proportion of children without severe hypotension
transfused in each of the three randomised arms was simi-
lar (468/1,024 (46%), 470/1,015 (46%), and 438/1,015
(43%) in the albumin bolus arm, saline bolus arm, and no
bolus arm, respectively). Of the 28/3,082 children
Figure 2 Forest plot comparing 48-hour mortality in fluid bolus and control groups, by admission haemoglobin level.
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randomised to receive albumin or saline bolus, 11 (38%)
were also transfused.
In total, 94% (933/1,002) of severely anaemic children
were transfused, with 275/933 (29%) receiving more than
two transfusions, this proportion varying from ≤5% inKenya and Tanzania to between 23% and 38% in the four
Ugandan centres; 70% (351/501) with moderate anaemia
and 12% (99/843) with mild anaemia were transfused,
of whom 41 (8%) children with moderate anaemia
and one child with mild anaemia received two or more
transfusions.
Table 3 Clinical predictors of transfusion in children with admission Hb ≥5 g/dL
Univariable analyses1 Multivariable analyses (n = 1,962)
Variable Number in
univariate model
HR (95% CI) P value2 HR (95% CI) P value2
Updated (most recent) haemoglobin (per 1 g/dL increase) – – 0.46 (0.41–0.52) <0.001
Haemoglobin at admission (per 1 g/dL increase) – – 0.84 (0.74–0.95) 0.005
Severe pallor 2,076 3.21 (2.47–4.19) <0.001 3.18 (2.42–4.19) <0.001
Jaundice (clinical) 2,079 1.57 (1.30–1.89) <0.001 1.27 (0.97–1.68) 0.08
Haemoglobinuria 2,078 1.69 (1.28–2.21) <0.001 – –
P. falciparum malaria 2,072 1.42 (1.13–1.80) 0.003 – –
Weak pulse volume 2,080 1.37 (1.10–1.70) 0.005 – –
Severe tachycardia 2,079 0.88 (0.71–1.10) 0.26 0.80 (0.63–1.00) 0.054
Capillary refill time ≥3 s 2,079 1.58 (1.27–1.97) <0.001 1.59 (1.24–2.03) 0.001
Temperature gradient 2,080 1.30 (1.07–1.58) 0.007 – –
Respiratory distress 2,072 1.23 (0.96–1.58) 0.09 – –
Indrawing 2,080 1.24 (1.02–1.51) 0.04 1.30 (1.01–1.69) 0.04
Deep breathing 2,080 1.24 (1.07–1.44) 0.005 – –
Dehydration 2,078 1.27 (0.93–1.74) 0.14 1.33 (0.95–1.85) 0.09
Lactate at admission (per 1 mmol/L increase) 1,970 1.09 (1.07–1.17) <0.001 1.08 (1.05–1.10) <0.001
Oxygen saturation (per 1% increase) 2,047 1.00 (0.99–1.02) 0.91 – –
Consciousness level 2,078 0.22 – –
Alert 1 (ref) – –
Prostration 1.26 (0.97–1.65) 0.09 – –
Coma 1.22 (0.88–1.68) 0.24 – –
Site 2,080 <0.001 <0.001
Mbale, Uganda 1 (ref) 1 (ref)
Kilifi, Kenya 0.44 (0.27–0.71) 0.001 0.38 (0.21–0.68) 0.001
Mulago, Uganda 0.91 (0.71–1.16) 0.44 0.98 (0.70–1.40) 0.93
Soroti, Uganda 1.18 (0.91–1.54) 0.21 1.39 (1.00–1.96) 0.05
Lacor, Uganda 0.63 (0.44–0.88) 0.008 0.71 (0.46–1.11) 0.13
Teule, Tanzania 1.35 (0.90–2.05) 0.15 1.56 (0.96–2.54) 0.08
1All models adjusted for baseline haemoglobin, most recent haemoglobin, and randomisation arm.
2P value for Likelihood ratio test overall or Wald test for categories.
Bacteraemia was not included in the model as only 1,071 children had a blood culture.
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sions, and packed red blood cells, which were only avail-
able at Mulago Hospital, for 308/1,767 (17%) transfusions.
Five transfused children received frusemide during their
clinical course in hospital.
Timing and indications for transfusion and re-transfusion
Among surviving severely anaemic children, 94% were
transfused by 8 hours, 96% by 24 hours, and 99% by
48 hours of admission (Figure 1). The proportion of
moderately anaemic children who were transfused in-
creased rapidly during the first 2 hours of admission,
and again between 8 and 10 hours, following repeat
Hb measurement at 8 hours. The proportion of chil-
dren with moderate anaemia who were transfused ateach time point varied significantly (P <0.001) between
centres (Additional file 1: Figure S1). Among 843 chil-
dren who were mildly anaemic on admission, 4% were
transfused by 8 hours, and 8% by 24 hours. Four chil-
dren with baseline Hb ≥10 g/dL were transfused dur-
ing the first 48 hours of admission when their Hb level
fell <6.5 g/dL.
A Cox regression model for time to first transfusion in
children with baseline Hb ≥5 g/dL and complete infor-
mation on clinical predictors of transfusion (n = 1,962,
428 transfused; Table 3) showed that although most re-
cent Hb level was a very strong clinical predictor of
transfusion, Hb at baseline, severe pallor, jaundice, capil-
lary refill time ≥3 seconds, lactate, and chest indrawing
were independent predictors. Children were more likely
Table 4 Prevalence of anaemia, number of blood transfusions and mortality, by site
Kenya Uganda Tanzania TOTAL
N (%) Kilifi Mulago Soroti Lacor Mbale Teule
Children with admission Hb 215 745 629 232 1,164 97 3,082
ADMISSION FINDINGS
Severe pallor 77 (36%) 310 (42%) 364 (58%) 122 (53%) 648 (56%) 54 (56%) 1,575 (51%)
Jaundice 1 (<1%) 55 (7%) 169 (27%) 27 (12%) 721 (62%) 1 (1%) 974 (32%)
Haemoglobinuria 1 (<1%) 46 (6%) 136 (22%) 26 (11%) 174 (15%) 2 (2%) 385 (13%)
Malaria parasitaemia 87 (40%) 369 (50%) 338 (54%) 160 (69%) 742 (64%) 53 (55%) 1,749 (57%)
BLOOD TRANSFUSION
All children
Received any transfusion (%) 45 (21%) 251 (34%) 332 (53%) 97 (42%) 616 (53%) 46 (47%) 1,387 (45%)
Received one or more
re-transfusions (% of those
transfused)
1 (2%) 82 (33%) 68 (20%) 14 (14%) 150 (24%) 2 (4%) 317 (23%)
Severe anaemia (Hb <5 g/dL)
At admission 28 (13%) 172 (23%) 269 (43%) 59 (25%) 452 (39%) 22 (23%) 1,002 (33%)
At 8 hours* 15/193 (8%) 93/704 (13%) 90/534 (17%) 40/204 (20%) 174/1,078 (16%) 16/83 (19%) 428/2,796 (15%)
At 24 hours* 13/191 (7%) 46/687 (7%) 59/568 (10%) 31/197 (16%) 89/1,032 (9%) 4/79 (5%) 242/2,754 (9%)
Received any transfusion (%) 26 (93%) 156 (91%) 250 (93%) 56 (95%) 425 (94%) 20 (91%) 933 (94%)
Received one or more
re-transfusions (% of those
transfused)
1 (4%) 65 (42%) 61 (24%) 14 (25%) 133 (31%) 1 (5%) 275 (29%)
Moderate anaemia
(Hb 5 to <7 g/dL)
At admission 32 (15%) 110 (15%) 81 (13%) 51 (22%) 204 (18%) 23 (24%) 501 (16%)
At 8 hours* 39/193 (20%) 191/704 (27%) 185/534 (35%) 68/204 (33%) 326/1,078 (30%) 27/83 (33%) 836/2,796 (30%)
At 24 hours* 39/191 (20%) 163/687 (24%) 182/568 (32%) 71/197 (36%) 329/1,032 (32%) 20/79 (25%) 804/2,754 (29%)
Received any transfusion (%) 16 (50%) 76 (69%) 58 (72%) 30 (59%) 150 (74%) 21 (91%) 351 (70%)
Received one or more
re-transfusions (% of those
transfused)
0 (0%) 17 (22%) 7 (12%) 0 (0%) 16 (11%) 1 (5%) 41 (12%)
Mild anaemia (Hb 7 to <10 g/dL)
At admission 88 (41%) 198 (27%) 148 (24%) 83 (36%) 301 (26%) 25 (26%) 843 (27%)
At 8 hours* 106/193 (55%) 267/704 (27%) 210/534 (39%) 75/204 (37%) 429/1,078 (39%) 32/83 (39%) 1,119/2,796 (40%)
At 24 hours* 105/191 (55%) 309/687 (45%) 239/568 (42%) 76/197 (39%) 474/1,032 (46%) 41/79 (52%) 1,244/2,754 (45%)
Received any transfusion (%) 3 (3%) 19 (10%) 22 (15%) 11 (13%) 40 (13%) 4 (16%) 99 (12%)
Received one or more
transfusions (% of those
transfused)
0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (3%) 0 (0%) 1 (1%)
MORTALITY
Died by 48 hours 21 (10%) 62 (8%) 58 (9%) 36 (16%) 108 (9%) 20 (21%) 305 (10%)
Died by 28 days 26 (12%) 76 (10%) 70 (11%) 41 (18%) 118 (10%) 22 (23%) 353 (12%)
*Denominators vary due to deaths or missing Hb values.
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(the largest site, used as the reference), although Mbale
had the highest proportion (13%) of children receiving
two or more transfusions. Although malaria parasitae-
mia, temperature gradient, weak pulse, deep breathing,and respiratory distress were associated with time to
transfusion in univariable models, they were not signi-
ficantly associated in the multivariable model. Severe
tachycardia, dehydration, prostration, coma and oxygen
saturation were not significantly associated with time to
Table 5 Clinical predictors of re-transfusion in children
transfused at least once (n = 1,387)
Admission variable Odds ratio (95% CI) P value
Haemoglobin at admission
(per 1 g/dL increase)
0.68 (0.60–0.76) <0.001
Lactate at admission
(per 1 mmol/L increase)
1.01 (0.98–1.05) 0.57
Consciousness level
Prostration (inability to sit or
breastfed if <8 months)
0.94 (0.62–1.44) 0.77
Coma (inability to localise
a painful stimulus)
0.25 (0.12–0.51) <0.001
Clinical jaundice 1.42 (0.98–2.06) 0.06
Indrawing 0.97 (0.66–1.41) 0.86
Deep breathing (Kussmaul’s
breathing)
1.30 (0.92–1.83) 0.14
Capillary refill time ≥3 s 1.08 (0.78–1.49) 0.65
Dehydration 1.64 (1.03–2.61) 0.04
Severe pallor* 14.4 (1.88–104.9) 0.01
Severe tachycardia 0.69 (0.51–0.93) 0.02
Site
Mbale, Uganda 1 (ref)
Kilifi, Kenya 0.15 (0.02–1.21) 0.08
Mulago, Uganda 2.36 (1.42–3.92) 0.001
Soroti, Uganda 0.82 (0.52–1.29) 0.39
Lacor, Uganda 0.84 (0.40–1.75) 0.64
Teule, Tanzania 0.29 (0.06–1.35) 0.12
*Only 7% of the children included in this model did not have pallor at
baseline and there are a small number of events in this group, giving a wide
confidence interval.
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dence of an association between randomisation arm and
risk of subsequent transfusion.
Factors predictive of re-transfusion among children
who were transfused at least once (n = 1,387) were admis-
sion Hb, coma, pallor, and severe tachycardia (Table 5).
Even when controlling for baseline Hb level, children at
Mulago hospital were twice as likely to be re-transfused
compared to the other sites.
Outcome of transfusion
Among 899 children who were severely anaemic at base-
line and transfused within 8 hours of admission, 8-hour
Hb level remained <5 g/dL in 227 (26%) and ≥5 g/dL in
591 (66%), while 39 (4%) children had died (Table 6).
For 103 severely anaemic children who were not trans-
fused in the first 8 hours, Hb level at 8 hours re-
mained <5 g/dL in 26 (25%) and ≥5 g/dL in 20 (19%),
while 54 (52%) children had died; 90% of these deaths
occurred within 2.5 hours of randomization and 100%
within 5 hours. Overall, 67% (93/139) of deaths among
severely anaemic children occurred within 8 hours of ad-
mission and 92% (128/139) by 24 hours. For 70% (89/128)
of the severely anaemic children who died within 24 hours,
mode of death was considered by an independent End-
point Review Committee, who were blind to the rando-
mised arm, to be cardiogenic (defined as signs of shock,
severe tachycardia or bradycardia plus one of prolonged
capillary refill time ≥3 seconds, cold peripheries, or low
blood pressure at the point of demise), and indicative of
myocardial dysfunction rather than biventricular failure
[14]. Among 184 children with moderate anaemia at base-
line who were transfused within the first 8 hours, Hb level
at 8 hours fell to <5 g/dL in 15 (8%) and was ≥5 g/dL in
148 (80%), while 10 (5%) children had died. For the 317
children with moderate anaemia who were not transfused
by 8 hours, Hb at 8 hours had fallen to <5 g/dL in
107 (34%) and was ≥5 g/dL in 184 (58%), while 12
(4%) had died. Of the 35 children with mild anaemia
who were transfused within the first 8 hours of ad-
mission, Hb level at 8 hours had fallen to <5 g/dL in
2 (6%) and was ≥5 g/dL in 23 (66%), while 8 (23%)
had died. Among the 808 children with mild anaemia
at baseline who were not transfused by 8 hours, 8-
hour Hb level was <5 g/dL in 14 (2%) and ≥10 g/dL
in 685 (85%), while 29 (4%) had died.
By 24 hours, 128/1,002 (13%) severely anaemic children
had died, compared to 36/501 (7%) moderately anaemic
and 71/843 (8%) mildly anaemic children. Mortality at
48 hours for children with a baseline Hb measurement
was 305/3,082 (10%), with 267/305 (88%) of all deaths oc-
curring within 24 hours of admission. Among the 3,054
children with a baseline Hb measurement but without se-
vere hypotension on admission, mortality in thoserandomised to receive fluid boluses of 0.9% saline or albu-
min was increased (10.6% and 10.5%, respectively), com-
pared to no-bolus controls (7.2%), regardless of admission
Hb level, and with no evidence of heterogeneity (P >0.3)
between any subgroups (Figures 2 and 3).
Blood transfusion reactions
Following blinded adjudication by the trial Endpoint
Review Committee, 6 of the 1,387 children in receipt of
one or more transfusions (0.4%) were considered to have
had a “probable” blood transfusion reaction. These chil-
dren all developed fever and an urticarial rash 1 to
3 hours after the start of blood transfusion. In all cases,
the transfusion was discontinued and the child treated
with intravenous hydrocortisone, with or without anti-
histamines. All children recovered fully.
Discussion
We have used data from a large randomised clinical trial
of fluid resuscitation strategies to describe the prevalence,
clinical features, and blood transfusion management of an-
aemia in children presenting to six hospitals in malaria-
Table 6 Mortality and haemoglobin level at 8 and 24 hours by transfusion and baseline anaemia status
Anaemia status at baseline
Severe Moderate Mild No anaemia Total
Hb <5 g/dL Hb 5 to <7 g/dL Hb 7 to <10 g/dL Hb ≥10 g/dL
Status at 8 hours 1,002 501 843 736 3,082
TRANSFUSED 899 184 35 0 1,118
Hb <5 g/dL 227 (26%) 15 (8%) 2 (6%) 0 (0%) 244 (22%)
Hb 5 to <7 g/dL 347 (39%) 57 (31%) 4 (11%) 0 (0%) 408 (37%)
Hb 7 to <10 g/dL 227 (25%) 79 (43%) 16 (46%) 0 (0%) 322 (29%)
Hb ≥10 g/dL 17 (2%) 12 (7%) 3 (9%) 0 (0%) 32 (3%)
Hb missing – as died before 8 hours 39 (4%) 10 (5%) 8 (23%) 0 (0%) 57 (5%)
Hb missing – other reason 42 (5%) 11(6%) 2 (6%) 0 (0%) 54 (5%)
NOT TRANSFUSED 103 317 808 736 1,964
Hb <5 g/dL 26 (25%) 107 (34%) 14 (2%) 1 (<1%) 148 (8%)
Hb 5 to <7 g/dL 7 (7%) 51 (16%) 39 (5%) 2 (<1%) 99 (5%)
Hb 7 to <10 g/dL 4 (4%) 6 (2%) 13 (2%) 1 (<1%) 24 (1%)
Hb ≥10 g/dL 9 (9%) 128 (40%) 685 (85%) 683 (93%) 1505 (77%)
Hb missing – as died before 8 hours* 54 (52%) 12 (4%) 29 (4%) 22 (3%) 117 (6%)
Hb missing – other reason 3 (3%) 13 (4%) 28 (3%) 27 (4%) 71 (4%)
Status at 24 hours 1,002 501 843 736 3,082
TRANSFUSED 919 305 71 2 1,297
Hb <5 g/dL 143 (16%) 20 (7%) 7 (10%) 0 (0%) 170 (13%)
Hb 5 to <7 g/dL 361 (39%) 96 (31%) 12 (17%) 0 (33%) 469 (36%)
Hb 7 to <10 g/dL 293 (32%) 141 (46%) 29 (41%) 2 (67%) 465 (36%)
Hb ≥10 g/dL 31 (3%) 21 (7%) 8 (11%) 0 (0%) 60 (5%)
Hb missing – as died before 24 hours 71 (8%) 19 (6%) 13 (18%) 0 (0%) 103 (8%)
Hb missing – other reason 20 (2%) 8 (3%) 2 (3%) 0 (0%) 30 (2%)
NOT TRANSFUSED 83 196 772 734 1,785
Hb <5 g/dL 10 (12%) 26 (13%) 8 (1%) 0 (0%) 44 (2%)
Hb 5 to <7 g/dL 5 (6%) 12 (6%) 17 (2%) 2 (<1%) 36 (2%)
Hb 7 to <10 g/dL 3 (4%) 4 (2%) 5 (<1%) 0 (0%) 12 (<1%)
Hb ≥10 g/dL 7 (8%) 131 (67%) 665 (86%) 674 (92%) 1,477 (83%)
Hb missing – as died before 24 hours 57 (69%) 17 (3%) 58 (8%) 32 (4%) 164 (9%)
Hb missing – other reason 1 (1%) 6 (3%) 19 (2%) 26 (4%) 52 (3%)
*90% of these children died within 2.5 hours of randomisation.
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vere febrile illness and clinical signs of impaired periph-
eral perfusion. The majority (76%) of the 3,082 children
in this study were anaemic on admission, while one
third (33%) were severely anaemic. The prevalence of
severe anaemia varied from 12% in Kenya to between
23 to 43% in Uganda, where an increased proportion
of children presented with jaundice, severe pallor, and
haemoglobinuria. Almost half of all patients (including
94% of those with severe anaemia) were transfused, while
10% received two or more transfusions. The frequency of
repeat transfusion varied between sites, from ≤2% in
Kenya and Tanzania to between 6% and 13% at the foursites in Uganda. Adherence to WHO transfusion guide-
lines was poor. There was no evidence of an association
between randomisation arm and risk of subsequent trans-
fusion. Adverse reactions to blood were rare (0.4%). In-
patient mortality at 48 hours was 10%, while 91% of all
deaths (92% among severely anaemic children) occurred
within 24 hours of admission. Among severely anaemic
children who were not transfused, 52% (54/103) had died
by 8 hours, and 90% of these deaths occurred within
2.5 hours of randomisation. Mortality among children
randomised to receive fluid boluses with saline or albumin
was significantly increased by 3.3% compared to controls,
regardless of admission Hb level.
Figure 3 Forest plot comparing 48-hour mortality in fluid bolus and control groups, by anaemia category.
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mia is highest among young children in low- and middle-
income regions [1]. Although micronutrient deficiencies,
infectious and parasitic diseases, and haemoglobinopathies
contribute to the multifactorial aetiology of severe child-
hood anaemia [15], malaria plays an important role in en-
demic areas [16]. The prevalence of severe anaemia in our
study sites was lowest in Kilifi, Kenya, where malaria
transmission is seasonal and of intermediate intensity, and
highest in Mbale and Soroti (Eastern Uganda), where mal-
aria transmission is perennial and intense [13]. The preva-
lence of confirmed bacteraemia (sepsis) was similar across
all anaemia categories.
To be eligible for the FEAST trial, children had to
have respiratory distress or impaired consciousness, plus
one or more signs of impaired perfusion. “Respiratory
distress” is a term used to describe the subjective clinical
impression of increased work of breathing. Historically,
respiratory distress in children with severe malarial an-
aemia has been considered synonymous with congestive
cardiac failure [17], though subsequent work suggests
that metabolic acidosis [18,19] and hypovolaemia [20-22]
may be central to the pathophysiology. The increased pro-
portion of severely anaemic children in this study with
clinical signs of dehydration, impaired peripheral perfu-
sion, hypotension, and severe lactic acidosis supports
this hypothesis. In contrast, the prevalence of chest
indrawing, an accepted feature of acute lower respira-
tory tract infections [5], was similar across each of the
anaemic and non-anaemic groups. Mortality of hospi-
talised children with asymptomatic severe malarial an-
aemia is ~1%, increasing to 35% when associated with
deep breathing and/or lactic acidosis and impaired
consciousness [23,24].
Clinicians participating in the FEAST trial were free to
follow WHO and national transfusion guidelines. WHOguidelines (on which most national guidelines are based)
advise transfusion for all children whose Hb level is 4 g/dL
or less, regardless of concomitant symptoms. Transfusion
guidance for children with Hb of 5 to 6 g/dL is less clear-
cut, since it depends upon the presence of one or more
additional clinical or laboratory criteria, for which the evi-
dence base is limited. Several of these criteria (“shock”,
“clinical dehydration”, “impaired consciousness”) are not
defined in the guidelines, while others (“cardiac failure”)
cannot be accurately diagnosed at the bedside. Malaria
parasitaemia (“malaria parasitaemia >10%”) is not rou-
tinely quantified in many hospitals throughout Africa.
When guidance is ambiguous, or in situations where clini-
cians lack confidence in the accuracy of Hb results pro-
duced by their local laboratory [25], their decision to
transfuse may be based on a subjective assessment of clin-
ical severity [26]. Our multivariable Cox regression model
suggests that transfusion of children with Hb ≥5 g/dL
was associated with pallor, prolonged capillary refill time,
lactate, and chest indrawing, but not with malaria parasit-
aemia, deep breathing, respiratory distress, prostration,
coma, or dehydration. Pallor is an unreliable predictor of
anaemia in hospital-based studies [27]. There is an urgent
need to obtain robust evidence on which clinical criteria
(if any) should be used to guide transfusion of children
with Hb levels of 5 to 6 g/dL [28].
As far as we are aware, this is the first report to docu-
ment the frequency of repeat blood transfusion among
patients with severe anaemia. Nearly half (45%) of all
children in this study were transfused, while 23% of
transfused children required re-transfusion. Children
presenting with severe anaemia in Uganda were 5 to 8
times more likely to receive a second transfusion than
children in Kenya or Tanzania, likely reflecting lower ad-
mission Hb levels (Table 4) and an increased proportion
of children (particularly in Mbale and Soroti) whose
Kiguli et al. BMC Medicine  (2015) 13:21 Page 12 of 13clinical presentation suggested intravascular haemolysis,
highlighting the importance of repeat Hb measurement
after blood transfusion, particularly in children with mal-
aria parasitaemia [10,29].
The highest proportion of repeat transfusions occurred
in Mulago hospital, Uganda (Table 4), the only site in
which packed red cells were routinely available. Although
this may reflect the increased ease of access to blood
banking facilities within this tertiary level teaching hos-
pital, it is possible that transfusion with 10 mL/kg of
packed red cells provided inadequate treatment for chil-
dren with severe anaemia.
The high proportion of repeat transfusions also sug-
gests that 20 mL/kg whole blood may be insufficient for
children with severe anaemia and ongoing haemolysis.
Current WHO transfusion guidelines [30] recommend
20 mL/kg of whole blood or 10 mL/kg packed cells for
children with Hb ≤6 g/dL, yet standard calculations in-
dicate that this under-treats children with profound an-
aemia (Hb <4 g/dL) by ~30% [31] Other researchers
have shown a modest rise in Hb of 2.5 to 3.3 g/dL fol-
lowing initial transfusion of 20 mL/kg [10,29,32], with
post-transfusion Hb remaining <5 g/dL in ~25% of se-
verely anaemic children [10], as we found here. Multiple,
low volume (20 mL/kg of whole blood) transfusions are
wasteful, inefficient, and may expose children to an in-
creased risk of transfusion reactions and blood-borne in-
fection. Recent evidence suggests that transfusion of
children with Hb <6 g/dL (median Hb 4.2 g/dL; inter-
quartile range, 3.1 to 4.9) with 30 mL/kg of whole blood
or 15 mL/kg of packed red cells is safe, and is associated
with accelerated haematological recovery [33]. This
needs to be confirmed in a larger number of children,
including those with Hb <3 g/dL, who may be compro-
mised by the cardio-depressant effects of profound
metabolic acidosis.
Although rapid blood transfusion in children with
severe decompensated anaemia can be lifesaving, the
majority of hospitals in sub-Saharan African have inad-
equate blood banking facilities and transfusion may be
delayed until a donor is found [2]. Consequently, ~60%
of deaths among children with severe malarial anaemia
occur within 4 to 6 hours of admission, often before
transfusion can be administered [9,10]. In our study,
90% of severely anaemic children were transfused during
the first 8 hours of admission, reflecting the efficiency of
local transfusion services. By 8 hours, 4% (39/899)
of these children had died, compared to 52% (54/103) of
those who were not transfused; 90% of these deaths oc-
curred within 2.5 hours of randomization, highlighting
the critical importance of prompt transfusion. In con-
trast, 8-hour mortality of children with mild anaemia
was higher among transfused children (8/35, 23%) than in
those who were not transfused (29/808, 4%), suggesting(though numbers are small) that clinical signs of severe ill-
ness, unrelated to anaemia, may have prompted the deci-
sion to transfuse. Confining blood transfusion to children
with moderate or severe anaemia would probably make
better use of a scarce commodity, and might have averted
some of the deaths that occurred among the severely an-
aemic children who were still awaiting transfusion at
8 hours.
The data presented here were obtained within the con-
text of a large randomised trial of fluid resuscitation
strategies for children with severe febrile illness and
signs of impaired perfusion. Our study population there-
fore represents the most severe end of the spectrum of
anaemic children presenting to hospital admission in
sub-Saharan Africa and concomitant morbidity and mor-
tality may consequently have been over-represented.
There has been much debate over whether the in-
creased mortality that was observed in the FEAST trial
among children randomised to receive fluid boluses of
0.9% saline or albumin was due to haemodilution of
children who were already compromised by critically
low levels of Hb [34-36] . However, mortality of children
who received fluid boluses was increased at all levels of
admission Hb (Figure 2), with no evidence of heterogen-
eity between subgroups, strongly suggesting that this
was not the case.
Conclusions
We have described the prevalence, clinical features,
and blood transfusion management of a large group
of severely ill children admitted to six hospitals in East
Africa. Our data confirm the importance of rapidly
identifying sick, severely anaemic children and ensuring
that they are promptly transfused. They also suggest
that adherence to current WHO transfusion guidelines,
even within the context of a clinical trial, is sub-optimal,
and that transfusion with 20 mL/kg whole blood or
10 mL/kg packed cells may undertreat a significant pro-
portion of anaemic children. A clinical trial to evaluate the
impact of using a larger volume of transfused blood and
determine the optimum transfusion management of chil-
dren with Hb of <6 g/dL is underway (TRACT trial:
ISRCTN84086586).
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